Diagnosing Alzheimer's Disease And Schizophrenia

Merril, C., Johnson, G., Ghanbari, H. (NIMH)

Filed 17 Jun 92

Serial No. 07/904,045

Alzheimer's disease represents the fourth leading cause of death in the United States, killing over 100,000 annually, and afflicting some 4 million Americans. Various reports indicate that the incidence of Alzheimer's disease increases with age and estimate that the prevalence of Alzheimer's disease in people over 80 years of age is between 20 and 50%. Schizophrenia occurs in approximately 1.5% of adults. Over 2.5 million people in the U.S. and nearly 47 million people worldwide suffer from schizophrenia. Under currently available technology Alzheimer's disease can only be presumptively diagnosed by pathological examination of brain tissue during autopsy in conjunction with a clinical history of dementia. In the diagnosis of schizophrenia, the clinician is limited to aberrations of behavior. Although there has previously been no generally accepted laboratory markers for either of these two diseases of the central nervous system it has been discovered that production of certain proteins is increased in acute phase reactions associated with these disorders. The present invention provides methods of diagnosing Alzheimer's disease and schizophrenia by detecting elevated levels of such proteins in a biological sample from a patient either by immunoassay or 2D-gel electrophoresis. [portfolio: Central Nervous System— Diagnostics]

Dated: July 6, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95-17780 Filed 7-19-95: 8:45 am] BILLING CODE 4140-01-P

National Heart, Lung, and Blood Institute; Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

Name of SEP: Race and Gender Differences in Sepsis Mediator Release (Telephone Conference Call).

Date: August 1, 1995.

Time: 1 p.m.

Place: Rockledge II, Room 7204, 6701 Rockledge Drive, Bethesda, Maryland.

Contact Person: Dr. Eric Brown, Rockledge II, Room 7204, 6701 Rockledge Drive, Bethesda, Maryland 20892, (301) 435-0299.

Purpose/Agenda

To review and evaluate contract proposals.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
This notice is being published less

than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: July 14, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-17776 Filed 7-19-95; 8:45 am] BILLING CODE 4140-01-M

Division of Research Grants; Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda

To review individual grant applications.

Name of SEP: Multidisciplinary Sciences. Date: August 3, 1995.

Time: 1 p.m. Place: NIH, Rockledge II, Room 5210, Telephone Conference.

Contact Person: Dr. Nadarajen Vvdelingum, Scientific Review Administrator, 6701 Rockledge Drive, Room 5210, Bethesda, MD 20892, (301) 435-1176.

Name of SEP: Behavioral and Neurosciences.

Date: August 7, 1995.

Time: 2 p.m.

Place: NÎH, Rockledge II, Room 5172, Telephone Conference.

Contact Person: Dr. Leonard Jakubczak, Scientific Review Administrator, 6701 Rockledge Drive, Room 5172, Bethesda, MD 20892, (301) 435-1247.

Name of SEP: Behavioral and Neurosciences.

Date: August 8, 1995.

Time: 2 p.m.

Place: NIH, Rockledge II, Room 5172, Telephone Conference.

Contact Person: Dr. Leonard Jakubczak, Scientific Review Administrator, 6701 Rockledge Drive, Room 5172, Bethesda, MD 20892, (301) 435-1247.

Name of SEP: Multidisciplinary Sciences. Date: August 9, 1995.

Time: 9 a.m.

Place: Holiday Inn, Chevy Chase, MD. Contact Person: Dr. Houston Baker, Scientific Review Administrator, 6701 Rockledge Drive, Room 5208, Bethesda, MD 20892, (301) 435–1175.

Name of SEP: Biological and Physiological Sciences.

Date: August 10, 1995.

Time: 2 p.m.

Place: NIH, Rockledge II, Room 6154, Telephone Conference.

Contact Person: Dr. David Redmondini, Scientific Review Administrator, 6701 Rockledge Drive, Room 6154, Bethesda, MD 20892, (301) 435-1038.

Name of SEP: Multidisciplinary Sciences. Date: August 11, 1995.

Time: 12 noon.

Place: NIH, Rockledge II, Room 5104,

Telephone Conference.

Contact Person: Dr. Donald Schneider, Scientific Review Administrator, 6701 Rockledge Drive, Room 5104, Bethesda, MD 20892, (301) 435-1165.

Name of SEP: Biological and Physiological Sciences.

Date: August 11, 1995.

Time: 2 p.m.

Place: NIH, Rockledge II, Room 6154, Telephone Conference

Contact Person: Dr. David Redmondini, Scientific Review Administrator, 6701 Rockledge Drive, Room 6154, Bethesda, MD 20892, (301) 435–1038.

Name of SEP: Clinical Sciences.

Date: August 16, 1995.

Time: 11 a.m.

Place: NIH, Rockledge II, Room 4136, Telephone Conference.

Contact Person: Dr. Gordon Johnson, Scientific Review Administrator, 6701 Rockledge Drive, Room 4136, Bethesda, MD 20892, (301) 435-1212.

Name of SEP: Clinical Sciences.

Date: August 21, 1995.

Time: 2 p.m.

Place: NÎH, Rockledge II, Room 4136, Telephone Conference.

Contact Person: Dr. Gordon Johnson, Scientific Review Administrator, 6701 Rockledge Drive, Room 4136, Bethesda, MD 20892, (301) 435-1212.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets of commercial property such as patentable material and personal information concerning individuals associated with the